Giáo trình Y học: Age-related Macular Degeneration Diagnosis and Treatment (Chẩn đoán và điều trị thoái hóa điểm vàng do tuổi tác)

ALLEN C. HO - CARL D. REGILLO

AGE-RELATED MACULAR DEGENERATION DIAGNOSIS AND TREATMENT

(CHẨN ĐOÁN VÀ ĐIỀU TRỊ THOÁI HÓA ĐIỂM VÀNG DO TUỔI TÁC)

PUBLISHER: SPRINGER (2011)

THÔNG TIN CHUNG:

Tên sách: Age-related Macular Degeneration Diagnosis and Treatment (tạm dịch: Chẩn đoán và điều trị thoái hóa điểm vàng do tuổi tác).

Tác giả: Allen C. Ho - Carl D. Regillo.

NXB: Springer (2011)

Số trang: 196

Cuốn sách giáo trình này được cấu trúc thành 10 chương chính sẽ cung cấp cho các nhà nghiên cứu, sinh viên, giảng viên cũng như y bác sĩ những kiến thức khoa học tiên tiến cũng như kinh nghiệm của các tác giả, các y bác sĩ đầu ngành về chứng thoái hóa điểm vàng do tuổi tác, một chứng bệnh lão hóa phổ biến trên thế giới, gây giảm thị lực và có nguy cơ gây mù lòa ở những người cao tuổi....

INTRODUCTION (GIỚI THIỆU):

The field of ophthalmology has witnessed an unparalleled degree of progress over the last decade in the diagnosis and management of age-related macular degeneration (AMD). Before ten years ago, diagnostic techniques consisted of only fundus angiography and treatment was limited to laser photocoagulation for neovascular AMD. Unfortunately, many people suffered severe and irreversible loss of visual acuity from advanced AMD, both neovascular and atrophic or nonneovascular.

A new era began around 1990 with the introduction of photodynamic therapy, which effectively limited vision loss due to certain angiographic classes of neovascular AMD but generally did not afford significant visual gains. More recently, injectable vascular endothelial growth factor (VEGF) Inhibiting pharmacotherapeutics have transformed the therapy of all types of neovascular AMD by giving patients a high likelihood of visual stability and a real chance of meaningful visual improvement Frequent intravitreal injections of anti-VEGF medicines remains the standard of care for neovascular AMD; However, there is still room for improvement since only the minority of patients experience significant visual gains and the treatment burden of frequent injections is high. The pace of finding even better therapies for neovascular AMD has quickened and new comparative information on anti-VEGF therapies will play a major role in treatment decision making.

Although the nutritional interventions established by the Age Related Eye

Disease Study (AREDS) Have incrementally improved the prognosis of patients with significant drusen and nonneovascular AMD, we have not yet witnessed a sea change event. This is about to change as our expanding understanding of the pathobiology of nonneovascular AMD points us toward new therapeutic strategies and targets. While all these therapeutic advances were emerging, our ability to diagnose AMD-related atrophy and exudation improved with the advent of fundus autofluorescence and optic coherence tomography (OCT). These invaluable tools have become essential for day-today patient care but also generate and measure important quantitative data in nearly all ongoing AMD clinical trials. Lastly, our understanding of disease has leaped forward with the discovery of various genetic factors and inflammatory mechanisms that are associated strongly with AMD.

This book aims to provide – for the retina specialist, general eye care professional, vision scientist, and those training in these areas – an update on the current understanding of AMD pathophysiology, the use of diagnostic tests, and the management of both nonneovascular and neovascular AMD. It also looks into the future with potential treatment options that are now under investigation in clinical trials. Finally, it covers the medical economics and societal impact of this major public health issue.

CONTENTS (MỤC LỤC):

1 Genetics of Age-Related Macular Degeneration

Daniel T. Kasuga, Yuhong Chen, and Kang Zhang

2 Modifiable Risk Factors of Age-Related Macular Degeneration

Hanna R. Coleman

3 Diagnosis of Age-Related Macular Degeneration

Jonathan Jonisch and Gaurav Shah

4 Fundus Imaging of Age-Related Macular Degeneration

Allen Chiang, Andre J. Witkin, Carl D. Regillo, and Allen C. Ho

5 Therapy of Nonexudative Age-Related Macular Degeneration

Annal D. Meleth, Veena R. Raiji, Nupura Krishnadev, and Emily Y. Chew

6 Management of Neovascular AMD

Fernando M. Penha and Philip J. Rosenfeld

7 Combination Therapy with Ocular Photodynamic Therapy for Age-Related Macular Degeneration

Nathan Steinle and Peter K. Kaiser

8 The Future of Non-neovascular Age-Related Macular Degeneration

Ketan Laud, Sri Krishna Mukkamala, Claudia Brue, and Jason S. Slakter

9 The Future of Neovascular Age-Related Macular Degeneration

Chirag P. Shah and Jeffrey S. Heier

10 The Economics of Age-Related Macular Degeneration

Gary C. Brown, Melissa M. Brown, Heidi B. Lieske, Philip A. Lieske, and Kathryn Brown

Index

REFERENCES (TÀI LIỆU THAM KHẢO):

1. Friedman DS, O’Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004; 122 (4): 564–72.

2. Seddon JM, Ajani UA, Mitchell BD. Familial aggregation of age-related maculopathy. Am J Ophthalmol. 1997; 123 (2): 199–206.

3. De Jong PT, Klaver CC, Wolfs RC, Assink JJ, Hofman A. Familial aggregation of age-related maculopathy. Am J Ophthalmol. 1997; 124 (6): 862–3.

4. Klaver CC, Wolfs RC, Assink JJ, van Duijn CM, Hofman A, de Jong PT. Genetic risk of age-related maculopathy. Population-based familial aggregation study. Arch Ophthalmol. 1998; 116 (12): 1646–51.

5. Silvestri G, Johnston PB, Hughes AE. Is genetic predisposition an important risk factor in age-related macular degeneration? Eye (Lond). 1994; 8 (Pt 5): 564–8.

6. Klein ML, Mauldin WM, Stoumbos VD. Heredity and age-related macular degeneration. Observations in monozygotic twins. Arch Ophthalmol. 1994; 112 (7): 932–7.

7. Meyers SM, Greene T, Gutman FA. A twin study of age-related macular degeneration. Am J Ophthalmol. 1995; 120 (6): 757–66.

8. Hammond CJ, Webster AR, Snieder H, Bird AC, Gilbert CE, Spector TD. Genetic influence on early age-related maculopathy: A twin study. Ophthalmology. 2002; 109 (4): 730–6.

9. Bressler SB, Munoz B, Solomon SD, West SK. Racial differences in the prevalence of age-related macular degeneration: The Salisbury Eye Evaluation (SEE) Project. Arch Ophthalmol. 2008; 126 (2): 241–5.

10. Friedman DS, Katz J, Bressler NM, Rahmani B, Tielsch JM. Racial differences in the prevalence of age-related macular degeneration: The Baltimore eye survey. Ophthalmology. 1999; 106 (6): 1049–55.

11. Klein R, Klein BE, Jensen SC, Mares-Perlman JA, Cruickshanks KJ, Palta M. Age-related maculopathy in a multiracial United States population: The national health and nutrition examination survey III. Ophthalmology. 1999; 106 (6): 1056–65.

12. Klein R, Klein BE, Knudtson MD, et al. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. Ophthalmology. 2006; 113 (3): 373–80.

13. Varma R, Fraser-Bell S, Tan S, Klein R, Azen SP. Prevalence of age-related macular degeneration in Latinos: The Los Angeles Latino eye study. Ophthalmology. 2004; 111 (7): 1288–97.

14. Kawasaki R, Yasuda M, Song SJ, et al. The prevalence of age-related macular degeneration in Asians: A systematic review and meta-analysis. Ophthalmology. 2010; 117: 921–7.

15. Abecasis GR, Yashar BM, Zhao Y, et al. Age-related macular degeneration: A high-resolution genome scan for susceptibility loci in a population enriched for late-stage disease. Am J Hum Genet. 2004; 74 (3): 482–94.

16. Iyengar SK, Song D, Klein BE, et al. Dissection of genomewide-scan data in extended families reveals a major locus and oligogenic susceptibility for age-related macular degeneration. Am J Hum Genet. 2004; 74 (1): 20–39.

17. Klein ML, Schultz DW, Edwards A, et al. Age-related macular degeneration. Clinical features in a large family and linkage to chromosome 1q. Arch Ophthalmol. 1998; 116 (8): 1082–8.

18. Majewski J, Schultz DW, Weleber RG, et al. Agerelated macular degeneration – a genome scan in extended families. Am J Hum Genet. 2003; 73 (3): 540–50.

19. Schmidt S, Scott WK, Postel EA, et al. Ordered subset linkage analysis supports a susceptibility locus for age-related macular degeneration on chromosome 16p12. BMC Genet. 2004; 5: 18.

20. Seddon JM, Santangelo SL, Book K, Chong S, Cote J. A genomewide scan for age-related macular degeneration provides evidence for linkage to several chromosomal regions. Am J Hum Genet. 2003; 73 (4): 780–90.

21. Weeks DE, Conley YP, Tsai HJ, et al. Age-related maculopathy: An expanded genome-wide scan withevidence of susceptibility loci within the 1q31 and 17q25 regions. Am J Ophthalmol. 2001; 132 (5): 682–92.

22. Weeks DE, Conley YP, Mah TS, et al. A full genome scan for age-related maculopathy. Hum Mol Genet. 2000; 9 (9): 1329–49.

23. Weeks DE, Conley YP, Tsai HJ, et al. Age-related maculopathy: A genomewide scan with continued evidence of susceptibility loci within the 1q31,10q26, and 17q25 regions. Am J Hum Genet. 2004; 75 (2): 174–89.

24. Fisher SA, Abecasis GR, Yashar BM, et al. Metaanalysis of genome scans of age-related macular degeneration. Hum Mol Genet. 2005; 14 (15): 2257–64.

25. Schultz DW, Klein ML, Humpert AJ, et al. Analysis of the ARMD1 locus: Evidence that a mutation in HEMICENTIN-1 is associated with age-related macular degeneration in a large family. Hum Mol Genet. 2003; 12 (24): 3315–23.

26. Anderson DH, Mullins RF, Hageman GS, Johnson LV. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol. 2002; 134 (3): 411–31.

27. Donoso LA, Kim D, Frost A, Callahan A, Hageman G. The role of inflammation in the pathogenesis of age-related macular degeneration. Surv Ophthalmol. 2006; 51 (2): 137–52.

28. Edwards AO, Ritter 3rd R, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. Science. 2005; 308 (5720): 421–4.

29. Johnson LV, Leitner WP, Staples MK, Anderson DH. Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp Eye Res. 2001; 73 (6): 887–96.

30. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005; 308 (5720): 385–9.

31. Mullins RF, Russell SR, Anderson DH, Hageman GS. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 2000; 14 (7): 835–46.

32. Scholl HP, Charbel Issa P, Walier M, et al. Systemic complement activation in age-related macular degeneration. PLoS ONE. 2008; 3 (7): E2593.

33. Sivaprasad S, Chong NV. The complement system and age-related macular degeneration. Eye (Lond). 2006; 20 (8): 867–72.

34. Giannakis E, Jokiranta TS, Male DA, et al. A common site within factor H SCR 7 responsible for binding heparin, CƯreactive protein and streptococcal M protein. Eur J Immunol. 2003; 33 (4): 962–9.

35. Thakkinstian A, Han P, McEvoy M, et al. Systematic review and meta-analysis of the association between complement factor H Y402H polymorphisms and age-related macular degeneration. Hum Mol Genet. 2006; 15 (18): 2784–90.

36. Seddon JM, Francis PJ, George S, Schultz DW, Rosner B, Klein ML. Association of CFH Y402H and LOC₃87715 A69S with progression of age-related macular degeneration. JAMA. 2007; 297 (16): 1793–800.

37. Ting AY, Lee TK, MacDonald IM. Genetics of agerelated macular degeneration. Curr Opin Ophthalmol. 2009; 20 (5): 369–76.

38. Grassi MA, Fingert JH, Scheetz TE. Ethnic variation in AMD-associated complement factor H polymorphism p. Tyr₄02His. Hum Mutat. 2006; 27 (9): 921–5.

39. Magnusson KP, Duan S, Sigurdsson H, et al. CFH Y402H confers similar risk of soft drusen and both forms of advanced AMD. PLoS Med. 2006; 3 (1): E5.

40. Maller J, George S, Purcell S, et al. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat Genet. 2006; 38 (9): 1055–9.

41. Cui L, Zhou H, Yu J, et al. Noncoding variant in the complement factor H gene and risk of exudative agerelated macular degeneration in a Chinese population. Invest Ophthalmol Vis Sci. 2010; 51 (2): 1116–20.

42. Li M, Atmaca-Sonmez P, Othman M, et al. CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration. Nat Genet. 2006; 38 (9): 1049–54.

43. Mori K, Gehlbach PL, Kabasawa S, et al. Coding and noncoding variants in the CFH gene and cigarette smoking influence the risk of age-related macular degeneration in a Japanese population. Invest Ophthalmol Vis Sci. 2007; 48 (11): 5315–9.

44. Gold B, Merriam JE, Zernant J, et al. Variation in factor B (BF) And complement component 2 (C₂) Genes is associated with age-related macular degeneration. Nat Genet. 2006; 38 (4): 458–62.

45. Spencer KL, Hauser MA, Olson LM, et al. Protective effect of complement factor B and complement component 2 variants in age-related macular degeneration. Hum Mol Genet. 2007; 16 (16): 1986–92.

46. Montes T, Tortajada A, Morgan BP, Rodriguez de Cordoba S, Harris CL. Functional basis of protection against age-related macular degeneration conferred by a common polymorphism in complement factor B. Proc Natl Acad Sci USA. 2009; 106 (11): 4366–71.

47. Despriet DD, van Duijn CM, Oostra BA, et al. Complement component C₃ and risk of age-related macular degeneration. Ophthalmology. 2009; 116 (3): 474–80. E472.

48. Maller JB, Fagerness JA, Reynolds RC, Neale BM, Daly MJ, Seddon JM. Variation in complement factor 3 is associated with risk of age-related macular degeneration. Nat Genet. 2007; 39 (10): 1200–1.

49. Spencer KL, Olson LM, Anderson BM, et al. C₃ R102G polymorphism increases risk of age-related macular degeneration. Hum Mol Genet. 2008; 17 (12): 1821–4.

50. Yates JR, Sepp T, Matharu BK, et al. Complement C₃ variant and the risk of age-related macular degeneration. N Engl J Med. 2007; 357 (6): 553–61.

Download Ebook: AGE-RELATED MACULAR DEGENERATION DIAGNOSIS AND TREATMENT

================================